/
Respiratory
Eosinophilic Esophagitis
14
Pipeline Programs↗
22
Active Trials↗
18
Companies Involved↗
Eosinophilic Esophagitis is an emerging landscape with 14 programs across 18 companies. The most active players are Bristol-Myers Squibb, Eupraxia Pharmaceuticals Inc.. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 1
No programs
Phase 24
Phase 33
Approved
No programs
Analysis
Modality Breakdown
92%
Small molecule
11 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.
Analysis
Trial Status
97
clinical trials
Completed58 · 60%
Active, not recruiting10 · 10%
Recruiting9 · 9%
Terminated8 · 8%
Withdrawn5 · 5%
Enrolling by invitation2 · 2%
Other5 · 5%
Clinical Trials
Trial Activity
97 trials
Zemaira Eosinophilic Esophagitis Pilot Study
Recruiting·—·Phase 2·NCT05485155·15 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)